-transparent.png){kind=logo}
Interleukin 12 (IL-12) activates natural killer (NK) and T cells with the secondary synthesis and release of interferon-gamma (IFN-gamma) and other cytokines. IL-12-induced organ alterations are reported for mice and the pathogenetic role of IFN-gamma is investigated by the use of mice deficient in the IFN-gamma receptor (IFN-gamma R-/-). IL-12 caused a rapid infiltration of liver and splenic red pulp with activated macrophages; this and increased NK cells resulted in a fivefold increase of splenic weight in wild-type mice. Splenomegaly was associated with myelosuppression and decreasing peripheral leukocyte counts. IL-12-induced changes in wild-type mice were associated with markedly increased IFN-gamma serum levels and up-regulation of major histocompatibility complex (MHC) class I and II expression in various epithelia. IL-12 induced a qualitatively similar macrophage infiltration in IFN-gamma R-/- mice, less marked splenomegaly (to 2 x normal), and no MHC upregulation. Strikingly increased vascular endothelial intercellular adhesion molecule-1 expression was apparent in both IFN-gamma R-/- and IFN-gamma R+/+ mice. Restricted to mutant mice was a severe, invariably lethal, interstitial, and perivascular pulmonary macrophage infiltration with diffuse pulmonary edema. Extensive quantitative reverse transcriptase polymerase chain reaction analysis revealed an increase of only IL-6 and IL-10 pulmonary gene transcripts in IFN-gamma R-/- mice compared with wild-type mice. IL-12-induced myelosuppression is due to IFN-gamma-release from NK cells and T cells, and is associated with macrophage activation and distinct MHC class I and II antigen upregulation. The pulmonary pathology in IFN-gamma R-/- mice, however, reveals a toxic potential for IL-12 and suggests that endogenous IFN-gamma plays a protective role in preventing fatal pulmonary disease in these mice.
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
October 1996,
Annals of the New York Academy of Sciences,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
April 1997,
Clinical immunology and immunopathology,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
March 2000,
European cytokine network,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
July 2001,
Experimental parasitology,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
March 1995,
European journal of immunology,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
February 1995,
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
March 2000,
Cytokines, cellular & molecular therapy,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
May 2009,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
February 2004,
Current opinion in pediatrics,
B D Car, and
V M Eng, and
B Schnyder, and
M LeHir, and
A N Shakhov, and
G Woerly, and
S Huang, and
M Aguet, and
T D Anderson, and
B Ryffel
February 2005,
Immunological reviews,
